このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Amylyx Pharmaceuticals マネジメント
マネジメント 基準チェック /24
Amylyx Pharmaceuticals'の CEO はJosh Cohenで、 Jan2013年に任命され、 の在任期間は 11.58年です。 の年間総報酬は$ 7.42Mで、 8.4%給与と91.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の4.14%を直接所有しており、その価値は$ 6.21M 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と3.6年です。
主要情報
Josh Cohen
最高経営責任者
US$7.4m
報酬総額
| CEO給与比率 | 8.4% |
| CEO在任期間 | 11.7yrs |
| CEOの所有権 | 0.6% |
| 経営陣の平均在職期間 | 3.7yrs |
| 取締役会の平均在任期間 | 3.7yrs |
経営陣の近況
Recent updates
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Sep 18
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Jun 25Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Apr 25Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates
Jul 18Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
Jul 04Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last
Jun 17CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$166m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$7m | US$621k | US$49m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$149m |
| Dec 31 2022 | US$7m | US$539k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$184m |
| Jun 30 2022 | n/a | n/a | -US$153m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$1m | US$418k | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$68m |
| Dec 31 2020 | US$671k | US$370k | -US$42m |
報酬と市場: Joshの 総報酬 ($USD 7.42M ) は、 US市場 ($USD 681.57K ) の同規模の企業の平均を上回っています。
報酬と収益: Joshの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Josh Cohen (32 yo)
11.7yrs
在職期間
US$7,418,169
報酬
Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 11.7yrs | US$7.42m | 0.56% $ 1.2m | |
| Co-Founder | 11.7yrs | US$7.42m | 4.03% $ 8.5m | |
| Chief Financial Officer | 3.7yrs | US$3.51m | 0.14% $ 297.9k | |
| Chief Legal Officer & General Counsel | 2.6yrs | US$3.01m | 0% $ 0 | |
| Chief Medical Officer | less than a year | US$2.37m | データなし | |
| Chief Technical Operations Officer | no data | データなし | データなし | |
| Head of Investor Relations & Communications | no data | データなし | データなし | |
| Head of Global Marketing | 3.8yrs | データなし | データなし | |
| Chief Human Resources Officer | less than a year | データなし | データなし | |
| Head of Canada & GM | 3.4yrs | データなし | データなし | |
| Head of Global Market Access | 3.8yrs | データなし | データなし | |
| Global Head of Regulatory Affairs | 4.1yrs | データなし | データなし |
3.7yrs
平均在職期間
53yo
平均年齢
経験豊富な経営陣: AMLXの経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 10.7yrs | US$7.42m | 0.56% $ 1.2m | |
| Co-Founder | 10.7yrs | US$7.42m | 4.03% $ 8.5m | |
| Company Secretary & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Special Advisor & Member of Advisory Board | 3.7yrs | US$51.24k | データなし | |
| Independent Chairman of the Board | 9.7yrs | US$385.07k | 1.26% $ 2.6m | |
| Chairman of The Scientific Advisory Board | no data | データなし | データなし | |
| Board Observer & Advisor | 7.2yrs | データなし | データなし | |
| Independent Director | 1.5yrs | US$681.15k | 0.081% $ 169.4k | |
| Independent Director | 3.3yrs | US$348.59k | 0.0073% $ 15.4k | |
| Independent Director | less than a year | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 3.5yrs | US$342.12k | 0.0058% $ 12.2k |
3.7yrs
平均在職期間
63yo
平均年齢
経験豊富なボード: AMLXの 取締役会 は 経験豊富 であると考えられます ( 3.6年の平均在任期間)。